U.S., Nov. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07934303) titled 'Study of NBIB-223 Gene Therapy in Friedreich's Ataxia (FACET)' on Nov. 06.
Brief Summary: This is a first-in-human study to evaluate the safety, tolerability, and pharmacodynamics of NBIB-0000223 (hereafter referred to as NBIB-223) in participants with Friedreich's Ataxia.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Friedreich's Ataxia
Intervention:
DRUG: NBIB-0000223
Intravenous (IV) infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Neurocrine Biosciences
Published by HT Digital Content Services with permission from Health Daily Digest....